Riegger, Guenter A. J. and Abletshauser, C. and Ludwig, M. and Schwandt, P. and Widimsky, J. and Weidinger, G. and Welzel, Dieter (1999) The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. ATHEROSCLEROSIS, 144 (1). pp. 263-270. ISSN 0021-9150,
Full text not available from this repository.Abstract
The primary objective of the present study was to investigate the cholesterol-lowering effect of fluvastatin on the incidence of cardiac events in hyperlipidaemic patients with symptomatic, clinically-diagnosed (exercise-ECG) coronary heart disease (CHD) during 1 year of treatment. Exercise tolerance, incidence of angina pectoris episodes, use of anti-anginal medication and intimal-medial-thickness (IMT subgroup) of the A. carotis were secondary endpoints. In the double-blind trial a total of 365 male and female patients with stable symptomatic CHD and a lour-density lipoprotein cholesterol (LDL-C) above 160 mg/dl on a lipid-lowering diet were randomised to fluvastatin 40 mg (o.a.d. or b.i.d.) or placebo for 1 year. Fluvastatin lowered total cholesterol by 17% and LDL-C by 27%. There was a significantly lower incidence of cardiac events (cardiac death, nonfatal myocardial infarction, unstable angina pectoris) in the fluvastatin group (3 events) as compared to the placebo group (10 events) (P<0.05). Exercise tolerance improved and the incidence of angina pectoris episodes decreased in both groups, but more pronounced on fluvastatin (n.s.). Exercise-EGG discontinuation due to angina pectoris and ST-segment depression decreased in the fluvastatin group by 55.6 and 70.9%, respectively, and in the placebo group by 39.6 and 46.5% (n.s.). At baseline, a subgroup of 76 patients showed a mean IMT value of 0.73 mm which remained uninfluenced in the fluvastatin and the placebo groups. Fluvastatin was safe and well tolerated. In conclusion, patients with symptomatic GHD get cardiovascular benefit from lipid-lowering therapy with fluvastatin even during the first year of treatment. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | AMERICAN-HEART-ASSOCIATION; LIPID-LOWERING THERAPY; SERUM-CHOLESTEROL; ATHEROSCLEROSIS-REGRESSION; MEDIAL THICKNESS; MEN; PROGRESSION; INTERVENTION; PRAVASTATIN; MECHANISMS; cardiac events; symptomatic coronary heart disease; fluvastatin; lipid-lowering |
| Subjects: | 600 Technology > 610 Medical sciences Medicine 600 Technology > 615 Pharmacy |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin II Chemistry and Pharmacy > Institute of Pharmacy > Pharmacology and Toxicology (Prof. Schlossmann, formerly Prof. Seifert) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 19 Oct 2022 12:50 |
| Last Modified: | 19 Oct 2022 12:50 |
| URI: | https://pred.uni-regensburg.de/id/eprint/48259 |
Actions (login required)
 |
View Item |
